Bright Green Corporation Stock

Equities

BGXX

US10920G1004

Pharmaceuticals

End-of-day quote Nasdaq 06:00:00 2024-04-21 pm EDT 5-day change 1st Jan Change
0.1981 USD -6.69% Intraday chart for Bright Green Corporation -11.96% -39.99%
Sales 2022 - Sales 2023 - Capitalization 60.7M
Net income 2022 -27M Net income 2023 -13M EV / Sales 2022 -
Net Debt 2022 3.66 Net Debt 2023 0.19 EV / Sales 2023 -
P/E ratio 2022
-2.75 x
P/E ratio 2023
-4.49 x
Employees 5
Yield 2022 *
-
Yield 2023
-
Free-Float 38.62%
More Fundamentals * Assessed data
Dynamic Chart
1 day-6.69%
1 week-11.96%
Current month-18.68%
1 month-26.08%
3 months-15.74%
6 months-52.27%
Current year-39.99%
More quotes
1 week
0.19
Extreme 0.186
0.24
1 month
0.19
Extreme 0.186
0.29
Current year
0.15
Extreme 0.15
0.54
1 year
0.15
Extreme 0.15
1.81
3 years
0.15
Extreme 0.15
58.00
5 years
0.15
Extreme 0.15
58.00
10 years
0.15
Extreme 0.15
58.00
More quotes
Managers TitleAgeSince
Director of Finance/CFO 39 22-02-28
47 -
Members of the board TitleAgeSince
Founder 66 19-04-15
Director/Board Member 51 19-12-31
Director/Board Member 57 21-06-30
More insiders
Date Price Change Volume
24-04-22 0.1981 -6.69% 500,400
24-04-19 0.2123 -4.63% 366,189
24-04-18 0.2226 +2.11% 424,394
24-04-17 0.218 -3.11% 242,220
24-04-16 0.225 -0.22% 161,564

End-of-day quote Nasdaq, April 21, 2024

More quotes
Bright Green Corporation is a provider of cannabis, cannabis-related products, and other legal medicinal plant-based therapies, manufactured in exact formulations for research and pharmaceutical applications and as an active ingredient to consumer-based solutions. The Company is engaged in cannabis propagation, cultivation, and manufacturing of cannabis products, including cannabis flower, pre-rolls, concentrates, vape pens, capsules, tinctures, edibles, topicals and any other cannabis-related products requested for authorized sales. The Company plans to sell extracted oils from medicinal plants grown in these high-tech facilities and processed onsite through a system that vertically integrates the genetically altered growth of the plants to conform to automated growing systems. It also plans to cultivate and manufacture cannabis for federally sanctioned research, as well as perform authorized research on cannabis, including cannabinol (CBN), cannabigerol (CBG), and cannabidiol (CBD).
Related indices
More about the company